Skip to main content
. 2020 Nov 13;73(2):606–624. doi: 10.1002/hep.31290

FIG. 1.

FIG. 1

Hepatic GPR55 mRNA is up‐regulated in patients with NAFLD. GPR55 mRNA levels in the liver of (A) participants without obesity and without NAFLD (n = 11) or participants with obesity and NAFLD (n = 35) (cohort 1), either grouped or considering the NAFL (n = 8) and NASH (n = 27) stages in two different groups, and (B) patients without obesity and without (n = 18) or with (n = 21) NAFLD (cohort 2), either grouped or considering the NAFL (n = 13) and NASH (n = 8) stages in two different groups. (C) Serum levels of the different species of LPI in patients with NASH (n = 78) compared with patients with fatty liver without NASH (n = 31) (cohort 3). HPRT was used to normalize mRNA levels. Data are presented as mean ± SEM. Statistical differences are denoted by *P < 0.05 and **P < 0.01. Abbreviations: GPR 55, G protein–coupled receptor 55; HPRT, hypoxanthine‐guanine phosphoribosyltransferase; LPI, l‐α‐lysophosphatidylinositol; NAFL, nonalcoholic fatty liver; NAFLD, NAFL disease; NASH, nonalcoholic steatohepatitis.